Just in case you haven't heard the news, 'There have been “very exciting” developments over the last decade in the treatment of CLL, Dr Kanti Rai (of CLL Rai staging fame) told HemOnc Today': healio.com/hematology-oncol...
Neil
Ibrutinib, idelalisib, venetoclax provide ‘ver... - CLL Support
Ibrutinib, idelalisib, venetoclax provide ‘very exciting developments’ in CLL - Dr Kanti Rai
AussieNeilAdministrator
Written by
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Not what you're looking for?
You may also like...
Vaccines, Ibrutinib toxicity,Dr. Rai on a cure, Dr Ghia on TP563 testing and ERIC
-effects-of-ibrutinib/
The one and only Dr. Kanti Rai talks both the elusive cure in CLL:...
Updated Results: Combined Ibrutinib and Venetoclax for 1st lineTreatment for CLL
regimen for pts with high-risk previously untreated CLL.
More here:...
Dr. Mato on what really happens when we must stop our ibrutinib or idelalisib
here. [ http://cllsociety.org/2016/05/ash-2015-happens-cll-patient-stop-ibrutinib-idelalisib ]
I...
ASH 2015: Dr. John M Pagel on the Problems with Idelalisib as Frontline Therapy in CLL
instead of the CLL Society website, but I thought the contrast of the broad approval of ibrutinib...
Related Posts
- Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease.
- ASCO 2014: Dr. Susan O'Brien Reviews the 3 years follow-up Data on Ibrutinib in CLL
- ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.
Dr. Wierda on the paradigm shift in CLL.
After 2 Vaccinations and 2 Boosters Still Zero Antibodies!!
